 |
05-May-08: Insilicos Awarded Grant for Life Science Computing 03-Apr-08: Insilicos Wins NIH Grant for Manufacturing 14-Jan-08: Insilicos Heart Disease Project Wins Research Funding 30-Aug-07: Insilicos Awarded $1 Million Grant for Biotech Services 30-Apr-07: Insilicos Names Heinecke to Chief Medical Advisor Post 22-Sep-06: Insilicos and GeneBio Sign Global Distribution Agreement 29-May-06: Insilicos Announces Breakthrough Proteomics Software Platform 28-Mar-06: Insilicos Announces 1000th Licensed User of InsilicosViewer 13-Mar-06: Insilicos Awarded Grant to Study Heart Disease 14-Feb-06: Insilicos CEO Erik Nilsson Interviewed 06-Feb-06: Insilicos Awarded Grant to Commercialize Proteomics Research 14-Sep-05: Insilicos announces support for biotech data format 31-Aug-05: Insilicos Announces Web Support for Biotech Tools 08-Jul-05: Insilicos appoints Teresa Skarr as Director of Regulatory Affairs 04-Jun-05: Insilicos Announces 500th Licensed User of InsilicosViewer 27-Apr-05: Insilicos Presents at Invest Northwest 31-Mar-05: Insilicos releases new version of viewer 23-Feb-05: Insilicos Awarded Proteomics Grant 14-Dec-04: Ruedi Aebersold joins Insilicos Advisory Board 01-Sep-04: InsilicosViewer in the News 15-Apr-04: Insilicos Wins NIH Grant 13-Oct-03: Insilicos Releases Beta 26-Jun-03: Insilicos Wins Grant 30-Sep-02: Insilicos Platform Project Announced
| |
|
Insilicos Awarded Grant to Commercialize Proteomics Research
|
|
Seattle, February 6, 2006: Insilicos today announced that the Washington Technology Center has awarded Insilicos a Research and Technology Development (RTD) grant to further development of its software tools aimed at detecting cardiovascular disease (CVD). Insilicos was one of eight Washington state companies given an RTD grant -- awarded to companies teamed with Washington researchers to commercialize new technologies.
Insilicos has developed software to more accurately analyze data obtained from analysis of plasma. The company is partnering with Dr. Tomas Vaisar, at the University of Washington to develop a faster, more affordable diagnostic test using the company's software. Through this grant, the new tool will be tested in the clinical setting. Insilicos is also exploring the application of this novel diagnostic tool for use by physicians to diagnose and treat other medical conditions, including diabetes.
Cardiovascular disease is the leading cause of death in the United States. Nearly one-quarter of all Americans has some form of CVD and six million patients are admitted to the hospital for treatment annually. Diagnostic tests that measure the ratio of different forms of cholesterol are the most common way to determine individuals at risk for heart disease. "But these tests miss most people who will develop heart disease -- at best they only identify 20-30% of the population at risk," said Kenneth Lans, M.D., Director of Clinical Products for Insilicos. "The medical community knows that new tests are needed that give a clearer, more accurate picture of which people really are at greater risk and thus should be getting appropriate and, often, more aggressive treatment.Insilicos LLC develops life science software for pharmaceutical development, biological research and clinical diagnostics.
For more information, visit the Insilicos web site www.insilicos.com or contact Insilicos at info@insilicos.com. 'Insilicos' and 'Life Science Software' are trademarks of Insilicos LLC.
|
|
